Pasithea Therapeutics Corp. — Director's Dealing 2022

Jun 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-06-21

Reporting Person: STEINMAN LAWRENCE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-21	Common Stock	A	652174	—	Acquired	1252174	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-02	Stock option (to acquire common stock)	$6.00	A	100000	Acquired	2031-08-02	Common Stock (600000)	Direct

Footnotes

F1: Represents shares of common stock of the Issuer issued in connection with the acquisition of the ALPHA-5 Integrin, LLC on June 21, 2022.

F2: The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to reporting person remaining employed and in good standing, one-half vesting on the first anniversary of the grant date, and the remainder vesting on the second anniversary of the grant date.